BRPI0511510A - composto, sais, solvatos, hidratos e pró-drogas farmaceuticamente aceitáveis do mesmo, composição, e, métodos para modular um receptor ativado com proliferador de peroxisoma, para tratar doença, para modular resistência à insulina, para tratar um ou mais fatores de risco para doença cardiovascular, para diminuir nìveis de fibrinogênio, para diminiuir ldlc, para suprimir apetite, e para modular nìveis de leptina em um indivìduo - Google Patents

composto, sais, solvatos, hidratos e pró-drogas farmaceuticamente aceitáveis do mesmo, composição, e, métodos para modular um receptor ativado com proliferador de peroxisoma, para tratar doença, para modular resistência à insulina, para tratar um ou mais fatores de risco para doença cardiovascular, para diminuir nìveis de fibrinogênio, para diminiuir ldlc, para suprimir apetite, e para modular nìveis de leptina em um indivìduo

Info

Publication number
BRPI0511510A
BRPI0511510A BRPI0511510-8A BRPI0511510A BRPI0511510A BR PI0511510 A BRPI0511510 A BR PI0511510A BR PI0511510 A BRPI0511510 A BR PI0511510A BR PI0511510 A BRPI0511510 A BR PI0511510A
Authority
BR
Brazil
Prior art keywords
decrease
modulating
treating
levels
pharmaceutically acceptable
Prior art date
Application number
BRPI0511510-8A
Other languages
English (en)
Inventor
Yan Zhu
Jingyuan Ma
Peng Cheng
Zuchun Zhao
Francine M Gregoire
Vera A Rakhmanova
Original Assignee
Metabolex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolex Inc filed Critical Metabolex Inc
Publication of BRPI0511510A publication Critical patent/BRPI0511510A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSTO, SAIS, SOLVATOS, HIDRATOS E PRó-DROGAS FARMACEUTICAMENTE ACEITáVEIS DO MESMO, COMPOSIçãO, E, MéTODOS PARA MODULAR UM RECEPTOR ATIVADO COM PROLIFERADOR DE PEROXIMSOMA, PARA TRATAR DOENçA, PARA MODULAR RESISTêNCIA à INSULINA, PARA TRATAR UM OU MAIS FATORES DE RISCO PARA DOENçA CARDIOVASCULAR, PARA DIMINUIR NìVEIS DE FIBRINOGêNIO, PARA DIMINUIR LDLC, PARA SUPRIMIR APETITE, E PARA MODULAR NìVEIS DE LEPTINA EM UM INDIVìDUO A presente invenção refere-se a determinados compostos inéditos de triazol representados pela Fórmula I e sais, solvatos, hidratos, e pró-drogas farmaceuticamente aceitáveis dos mesmos. A presente invenção refere-se também a métodos de preparar e usar referidos compostos para tratar ou controlar diversas doenças mediadas com PPAR, como metabolismo da glicose, metabolismo dos lipídeos e secreção de insulina, especificamente diabetes de tipo 2, hiperinsulinemia, hiperlipidernia, hiperuricemia, hipercolesterolemia, aterosclerose, um ou mais fatores de risco para doença cardiovascular, Síndrome X, hipertrigliceridemia, hiperglicemia, obesidade e distúrbios da alimentação.
BRPI0511510-8A 2004-05-25 2005-05-24 composto, sais, solvatos, hidratos e pró-drogas farmaceuticamente aceitáveis do mesmo, composição, e, métodos para modular um receptor ativado com proliferador de peroxisoma, para tratar doença, para modular resistência à insulina, para tratar um ou mais fatores de risco para doença cardiovascular, para diminuir nìveis de fibrinogênio, para diminiuir ldlc, para suprimir apetite, e para modular nìveis de leptina em um indivìduo BRPI0511510A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57442604P 2004-05-25 2004-05-25
PCT/US2005/018318 WO2005115383A2 (en) 2004-05-25 2005-05-24 Substituted triazoles as modulators of ppar and methods of their preparation

Publications (1)

Publication Number Publication Date
BRPI0511510A true BRPI0511510A (pt) 2007-12-26

Family

ID=35451382

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511510-8A BRPI0511510A (pt) 2004-05-25 2005-05-24 composto, sais, solvatos, hidratos e pró-drogas farmaceuticamente aceitáveis do mesmo, composição, e, métodos para modular um receptor ativado com proliferador de peroxisoma, para tratar doença, para modular resistência à insulina, para tratar um ou mais fatores de risco para doença cardiovascular, para diminuir nìveis de fibrinogênio, para diminiuir ldlc, para suprimir apetite, e para modular nìveis de leptina em um indivìduo

Country Status (13)

Country Link
US (2) US7323480B2 (pt)
EP (1) EP1751120A4 (pt)
JP (1) JP2008500357A (pt)
KR (1) KR20070036076A (pt)
CN (1) CN1997633A (pt)
AU (1) AU2005247473A1 (pt)
BR (1) BRPI0511510A (pt)
CA (1) CA2567437A1 (pt)
IL (1) IL179496A0 (pt)
MX (1) MXPA06013581A (pt)
RU (1) RU2006145872A (pt)
WO (1) WO2005115383A2 (pt)
ZA (2) ZA200610650B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1997633A (zh) 2004-05-25 2007-07-11 麦它波莱克斯股份有限公司 作为ppar调节剂的取代的三唑及其制备方法
US7622491B2 (en) * 2004-08-13 2009-11-24 Metabolex Inc. Modulators of PPAR and methods of their preparation
EP1865954A4 (en) * 2005-03-21 2010-12-15 Metabolex Inc METHOD FOR AVOIDING OEDEM IN THE TREATMENT OR PREVENTION OF DISEASES AFFECTING PPAR GAMMA INCLUDING CANCER
ME01294B (me) 2007-11-27 2013-06-20 Ardea Biosciences Inc Nova jedinjenja i kompozicije i metode upotrebe
RU2492167C2 (ru) * 2007-12-18 2013-09-10 Актелион Фармасьютиклз Лтд Производные аминотриазола в качестве агонистов alх
UA109638C2 (uk) 2008-03-13 2015-09-25 Сполуки та спосіб зниження рівня сечової кислоти
WO2010071813A1 (en) * 2008-12-19 2010-06-24 Aryx Therapeutics, Inc. AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-α
RU2544862C2 (ru) * 2009-06-09 2015-03-20 Актелион Фармасьютиклз Лтд Фторированные аминотриазольные производные
CN103261194B (zh) * 2010-12-07 2016-02-24 埃科特莱茵药品有限公司 作为alx受体激动剂的噁唑基-甲醚衍生物
WO2013033432A1 (en) * 2011-09-03 2013-03-07 Adipocyte Therapeutics Inc Methods and compositions for treating type 2 diabetes and related conditions
IN2014MN01442A (pt) * 2012-01-18 2015-07-03 Daiichi Sankyo Co Ltd
US20140178456A1 (en) * 2012-08-30 2014-06-26 Udaya Sankar Devanaboyina Methods and compositions for treating type 2 diabetes and related conditions
TW201418242A (zh) 2012-10-26 2014-05-16 Du Pont 作為除草劑之經取代的三唑
US10181018B2 (en) * 2013-03-14 2019-01-15 The University Of Toledo Analogs of proxisome proliferator activated receptor (PPAR) agonists and methods of using the same
CN103304504B (zh) * 2013-06-02 2015-03-04 张远强 一种抗糖尿病化合物、其制备方法和用途
CN103467398B (zh) * 2013-09-03 2015-01-21 浙江医药高等专科学校 三唑酰胺类化合物、其制备方法和其抗糖尿病用途
WO2015035171A1 (en) 2013-09-09 2015-03-12 High Point Pharmaceuticals, Llc Use of a ppar-delta agonist for treating muscle atrophy
WO2016057656A1 (en) * 2014-10-08 2016-04-14 Mitobridge, Inc. Ppar-delta agonists for use for treating mitochondrial, vascular, muscular, and demyelinating diseases
WO2016057322A1 (en) 2014-10-08 2016-04-14 Salk Institute For Biological Studies Ppar agonists and methods of use thereof
ES2643856B1 (es) * 2016-05-24 2018-08-03 Universidad Del Pais Vasco / Euskal Herriko Unibertsitatea Triazoles para la regulación de la homeostasis de calcio intracelular
ES2859487T3 (es) * 2016-10-05 2021-10-04 Mitobridge Inc Métodos para tratar las lesiones renales agudas
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease
CN116650490B (zh) * 2023-06-07 2025-05-20 中国人民解放军海军军医大学 化合物mt-1207在降低尿酸方面的应用

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US381644A (en) * 1888-04-24 Cloth-cutting machine
US344299A (en) * 1886-06-22 Cotton-gin feeder
NL74787C (pt) 1950-11-13
US3158645A (en) 1958-02-13 1964-11-24 Hooker Chemical Corp 2, 3, 6-trichlorobenzyl-2, 4-dichlorophenoxy-acetate
US3444299A (en) 1964-02-07 1969-05-13 American Cyanamid Co Methods for the control and prevention of helminths with phenylbenzothiazolium compounds
GB1097053A (en) 1964-03-16 1967-12-29 Dow Chemical Co Substituted benzothiazolium compounds and complexes thereof for use in animal husbandry
US3378582A (en) 1964-03-20 1968-04-16 Merck & Co Inc (alpha-phenoxy)-and (alpha-phenylthio)-omegaphenyl-alkanoic acids
US3517051A (en) 1964-03-20 1970-06-23 Merck & Co Inc Phenoxy substituted phenylacetic acids
US3517050A (en) 1966-10-03 1970-06-23 Merck & Co Inc Ester and amide derivative of (3-trifluoromethylphenoxy) (4 - halophenyl)acetic acid
US3558778A (en) 1966-10-27 1971-01-26 Dow Chemical Co Methods and compositions for use in animal husbandry
US3564042A (en) 1967-03-17 1971-02-16 Sandoz Ag Derivatives of acetic acid
US3546229A (en) 1967-07-14 1970-12-08 Sandoz Ag Derivatives of acetic acid
US3707549A (en) 1967-12-05 1972-12-26 Lilly Co Eli Alpha-substituted hydrocinnamic acids and derivatives thereof
US3674836A (en) 1968-05-21 1972-07-04 Parke Davis & Co 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
BE754245A (fr) 1969-08-01 1970-12-31 Sumitomo Chemical Co Derives d'acides phenoxy carboxyliques
US3816446A (en) 1972-04-11 1974-06-11 Merck & Co Inc (alpha-(3-trifluoromethylphenoxy)-4-chlorobenzyl)heterocycles
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3860628A (en) 1972-07-13 1975-01-14 Merck & Co Inc Cyanomethyl(3-trifluoromethylphenoxy)(4-chlorophenyl)acetate
US3953490A (en) 1972-07-13 1976-04-27 Merck & Co., Inc. Preparation of (3-trifluoromethylphenoxy)(4-chlorophenyl)acetonitrile
NL7309039A (pt) 1972-07-13 1974-01-15
JPS4951243A (pt) 1972-07-13 1974-05-18
US3923855A (en) 1972-07-13 1975-12-02 Merck & Co Inc 2-sulfonyloxyethyl 3-trifluoromethylphenoxy-4{40 -chlorophenyl acetate
NL7309571A (pt) 1972-07-28 1974-01-30
DE2358789A1 (de) 1973-02-07 1975-06-05 Merck Patent Gmbh Hydratropasaeure-derivate und verfahren zu ihrer herstellung
US4110351A (en) 1973-04-02 1978-08-29 Richardson-Merrell Inc. Hypolipidemic agents RO- or RS- substituted furoic acids, esters and salts
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3876791A (en) 1973-11-30 1975-04-08 Uniroyal Inc Control of acarids using certain benzothiazoles or benzothiazolines
US4001268A (en) 1974-08-07 1977-01-04 The United States Of America As Represented By The Secretary Of The Air Force Substituted phenyl-benzimidazo compounds
IL48707A0 (en) 1974-12-30 1976-02-29 Synthelabo Novel phenylacetic acid derivatives,their preparation and pharmaceutical compositions containing them
ZA765075B (en) 1975-09-25 1977-08-31 American Cyanamid Co Hypolipemic compounds and method of treatment
US4168385A (en) 1975-09-25 1979-09-18 American Cyanamid Company Hypolipemic phenylacetic acid derivatives
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
JPS6039072B2 (ja) 1976-07-28 1985-09-04 藤沢薬品工業株式会社 Ｎ−置換フエニルアミノ脂肪酸誘導体
JPS5371071A (en) 1976-12-08 1978-06-24 Teijin Ltd Alpha-phenoxyacetic acid derivs.
US4250191A (en) 1978-11-30 1981-02-10 Edwards K David Preventing renal failure
SE8003277L (sv) 1979-05-04 1980-11-05 Continental Pharma Bensimidazolderivat, deras framstellning och anvendning samt kompositioner innehallande dessa derivat
US4532135A (en) 1981-02-09 1985-07-30 Edwards K David G Renoprotective treatments employing vasodilator compounds
US4508882A (en) 1981-08-24 1985-04-02 Asahi Glass Company Ltd. Benzotriazole compound and homopolymer or copolymers thereof
EP0077938A3 (en) 1981-10-23 1983-08-24 Mitsubishi Kasei Corporation N-(3-substituted aminophenyl) tetrahydrophthalimides and herbicidal composition
DE3236730A1 (de) 1982-10-04 1984-04-05 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von benzoxazolyl- und benzthiazolyloxyphenoxypropionsaeurederivaten
US4580882A (en) * 1983-04-21 1986-04-08 Benjamin Nuchman Continuously variable contact lens
US4528311A (en) 1983-07-11 1985-07-09 Iolab Corporation Ultraviolet absorbing polymers comprising 2-hydroxy-5-acrylyloxyphenyl-2H-benzotriazoles
JPS60109578A (ja) 1983-11-17 1985-06-15 Mitsubishi Chem Ind Ltd ３−（置換フエニル）−５−置換−１，３，４−オキサゾリン−２−オン類およびこれを有効成分とする除草剤
DE3525284A1 (de) 1985-07-16 1987-01-29 Boehringer Mannheim Gmbh Neue carbonsaeurederivate, verfahren zu ihrer herstellung, ihre verwendung sowie arzneimittel, die diese verbindungen enthalten
US4714762A (en) 1986-10-31 1987-12-22 Warner-Lambert Company Antiarteriosclerotic substituted benzimidazol-2-yl-and 3H-imidazo[4,5-b]pyridin-2-yl-phenoxy-alkanoic acids and salts and esters thereof
JPH0670025B2 (ja) 1987-08-07 1994-09-07 鐘紡株式会社 ベンゾチアゾ−ル誘導体および該化合物を有効成分とする抗リウマチ剤
GB8720365D0 (en) 1987-08-28 1987-10-07 Sandoz Ltd Organic compounds
US4863802A (en) 1987-12-31 1989-09-05 General Electric Company UV-stabilized coatings
JPH01305069A (ja) 1988-05-31 1989-12-08 Shionogi & Co Ltd ベンゾトリアゾール誘導体およびそれを含有する発螢光試薬
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
CA2034309C (en) 1990-01-22 1997-04-01 Takashi Iwaki Mesomorphic compound, liquid crystal composition containing same, liquid crystal device using same and display apparatus
US5041640A (en) 1990-09-20 1991-08-20 Warner-Lambert Company Process for mono-, di-, trisubstituted acetic acids
US5278314A (en) 1991-02-12 1994-01-11 Ciba-Geigy Corporation 5-thio-substituted benzotriazole UV-absorbers
US5605930A (en) 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
DE4303676A1 (de) 1993-02-09 1994-08-11 Bayer Ag 1-Aryltriazolin(thi)one
US5874431A (en) 1993-08-28 1999-02-23 Cancer Research Campaign Technology Limited Benzazole compounds
US5496826A (en) 1994-09-02 1996-03-05 Bristol-Myers Squibb Company Pharmaceutical methods of using heterocyclic derivatives of N-phenylamides
US5455152A (en) 1994-09-27 1995-10-03 Eastman Kodak Company Benzotriazole based UV absorbing monomers and photographic elements containing polymers formed from them
US5700819A (en) 1994-11-29 1997-12-23 Grelan Pharmaceutical Co., Ltd. 2-substituted benzothiazole derivatives and prophylactic and therapeutic agents for the treatment of diabetic complications
US5518625A (en) 1995-02-13 1996-05-21 Uop Chiral separations by simulated moving bed chromatography operating at low k' values
IL117208A0 (en) 1995-02-23 1996-06-18 Nissan Chemical Ind Ltd Indole type thiazolidines
GB9503946D0 (en) 1995-02-28 1995-04-19 Cancer Res Campaign Tech Benzazole compounds
US5500332A (en) 1995-04-26 1996-03-19 Eastman Kodak Company Benzotriazole based UV absorbers and photographic elements containing them
JPH0927811A (ja) * 1995-07-13 1997-01-28 Fujitsu Ltd 輻輳監視制御装置
WO1997028149A1 (en) 1996-02-02 1997-08-07 Merck & Co., Inc. Method for raising hdl cholesterol levels
KR0183844B1 (ko) 1996-04-30 1999-05-15 김광호 알에프 발생 장치 및 이를 이용한 펄스 플라즈마 형성 방법
US5766834A (en) 1996-05-17 1998-06-16 Eastman Kodak Company Photographic element containing ultraviolet absorbing polymer
US5716987A (en) 1996-06-21 1998-02-10 Bristol-Myers Squibb Company Prophylactic and therapeutic treatment of skin sensitization and irritation
DE19631553A1 (de) 1996-07-26 1998-01-29 Arnold & Richter Kg Vorrichtung zum Fokussieren eines Filmbildes
WO1998006703A1 (en) 1996-08-14 1998-02-19 Warner-Lambert Company 2-phenyl benzimidazole derivatives as mcp-1 antagonists
WO1998023252A1 (en) 1996-11-22 1998-06-04 Ciba Specialty Chemicals Holding Inc. Use of selected benzotriazole derivatives for protecting human and animal skin and hair from the harmful effects of uv radiation
JP3714574B2 (ja) 1997-03-26 2005-11-09 ダイセル化学工業株式会社 紫外線吸収剤とその製造方法および合成樹脂組成物
CA2295930C (en) 1997-07-24 2010-12-14 Yamanouchi Pharmaceutical Co., Ltd. Pharmaceutical compositions having cholesterol-lowering effect
US5942532A (en) 1997-09-05 1999-08-24 Ortho Pharmaceutical Corporation 2-substituted phenyl-benzimidazole antibacterial agents
WO1999024425A1 (en) 1997-11-07 1999-05-20 Taiho Pharmaceutical Co., Ltd. Benzimidazole derivatives and pharmaceutically acceptable salts thereof
WO1999062885A1 (en) 1998-06-05 1999-12-09 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents
US6013659A (en) 1998-09-04 2000-01-11 University Of Pittsburgh Methods of reducing tumor colony number using novel benzothiazole compounds
HUP0104987A3 (en) 1998-12-18 2002-09-30 Axys Pharmaceuticals Inc South Benzimidazole or indole derivatives protease inhibitors, and pharmaceutical compositions containing them
US7576131B2 (en) 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US6262118B1 (en) 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US6624194B1 (en) 1999-06-04 2003-09-23 Metabolex, Inc. Use of (−) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
US6417212B1 (en) 1999-08-27 2002-07-09 Eli Lilly & Company Modulators of peroxisome proliferator activated receptors
NZ514403A (en) 1999-12-27 2002-10-25 Japan Tobacco Inc Fused-ring compounds and use thereof as drugs
US7078422B2 (en) 2001-03-23 2006-07-18 Nippon Chemiphar Co., Ltd. Activator for peroxisome proliferator-activated receptor
US20040077659A1 (en) 2002-02-21 2004-04-22 Oliver Jr William Roland Method for treating ppar gamma mediated diseases or conditions
US6867224B2 (en) 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
US20030207924A1 (en) 2002-03-07 2003-11-06 Xue-Min Cheng Compounds that modulate PPAR activity and methods of preparation
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
CA2479338A1 (en) 2002-03-20 2003-10-02 Metabolex, Inc. Substituted phenylacetic acids
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
BR0312503A (pt) * 2002-07-09 2007-06-26 Bristol Myers Squibb Co derivados heterocìclicos substituìdos úteis como agentes antidiabéticos e antiobesidade, composição farmacêutica, uso e combinação dos mesmos
US20040204472A1 (en) 2003-03-04 2004-10-14 Pharmacia Corporation Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents
AP2005003418A0 (en) * 2003-04-15 2005-12-31 Pfizer Alpha substituted carboxylic acids as ppar modulators.
US7199259B2 (en) 2003-06-20 2007-04-03 Metabolex, Inc. Resolution of α-(phenoxy)phenylacetic acid derivatives
CA2535665A1 (en) * 2003-08-14 2005-02-24 Asahi Kasei Pharma Corporation Substituted arylalkanoic acid derivative and use thereof
CN1997633A (zh) 2004-05-25 2007-07-11 麦它波莱克斯股份有限公司 作为ppar调节剂的取代的三唑及其制备方法

Also Published As

Publication number Publication date
ZA200610650B (en) 2009-04-29
KR20070036076A (ko) 2007-04-02
WO2005115383A3 (en) 2006-08-17
US20060014809A1 (en) 2006-01-19
IL179496A0 (en) 2007-05-15
EP1751120A4 (en) 2010-05-05
CA2567437A1 (en) 2005-12-08
MXPA06013581A (es) 2007-03-15
CN1997633A (zh) 2007-07-11
RU2006145872A (ru) 2008-06-27
US7323480B2 (en) 2008-01-29
US20080108630A1 (en) 2008-05-08
EP1751120A2 (en) 2007-02-14
ZA200801100B (en) 2008-09-25
JP2008500357A (ja) 2008-01-10
WO2005115383A2 (en) 2005-12-08
AU2005247473A1 (en) 2005-12-08

Similar Documents

Publication Publication Date Title
BRPI0511510A (pt) composto, sais, solvatos, hidratos e pró-drogas farmaceuticamente aceitáveis do mesmo, composição, e, métodos para modular um receptor ativado com proliferador de peroxisoma, para tratar doença, para modular resistência à insulina, para tratar um ou mais fatores de risco para doença cardiovascular, para diminuir nìveis de fibrinogênio, para diminiuir ldlc, para suprimir apetite, e para modular nìveis de leptina em um indivìduo
AP1772A (en) Compounds that modulate PPAR activity and methods for their preparation.
BR0210167A (pt) Composto, composição farmacêutica, métodos para modular um receptor ativado com proliferador de peroxissoma, para tratar ou prevenir uma doença ou condição e para abaixar a glicose no sangue, e, uso de um composto
PT1076644E (pt) Aminotetralinas substituidas emn como ligandos para o receptor de neuropeptideoy y5 util no tratamento da obesidade e de outras perturbacoes
MXPA05011536A (es) Acidos carboxilicos substituidos con fenilo como inhibidores de la proteina tirosina fosfatasa-1b.
UA96308C2 (ru) Антагонисты рецептора глюкагона, композиция, которая содержит такие соединения, и их применение
BRPI0609595A8 (pt) composições e métodos para o controle, prevenção e tratamento da obesidade e desordens alimentares
ATE386715T1 (de) Modulatoren des peroxisomproliferatoraktivierten rezeptors
WO2008033455A3 (en) Biphenyl and heteroaryl phenyl derivatives as protein tyrosine phosphatases inhibitors
WO2002047712A3 (en) Peptide yy and peptide yy agonists for treatment of metabolic disorders
WO2008097428A3 (en) Compounds and compositions as modulators of gpr119 activity
MX2009006795A (es) Compuestos que tienen tanto actividades de antagonismo de receptor de angiotensina ii como actividades activadoras de receptores activados por proliferizador de peroxisomas gamma.
BR112012017949A2 (pt) composição farmacêutica para o tratamento de uma síndrome metabólica
EA200900940A1 (ru) Фармацевтическая композиция, содержащая пиразол-о-глюкозидное производное
WO2006055708A3 (en) Heterocycle substituted carboxylic acids for the treatment of diabetes
IL163144A (en) Substituted methylene amide derivatives, their preparation and use thereof for the preparation of medicaments
HRP20050103B1 (hr) N-aril supstituirani bifenilkarboksamidi kao inhibitori sekrecije apolipoproteina b
BRPI0507120A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação de receptores de cb1 e sua utilização
BRPI0415538A (pt) utilização de um derivado do pirazol para o preparo de medicamento úteis na prevenção e no tratamento das dislipidemias e das doenças associadas às dislipidemias e/ou à obesidade
WO2005115384A3 (en) Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation
SG149001A1 (en) N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b
WO2006020916A3 (en) Modulators of ppar and methods of their preparation
BR0309152A (pt) composto ou sais, solvatos, hidratos ou pró-drogas deste farmaceuticamente aceitáveis, composição, métodos para tratar ou prevenir uma doença ou condição, uma doença cardiovascular, uma dislipidemia, a hipertensão, o cáncer, a inflamação, e a impotência em um paciente, forma de dosagem unitária, e, método para identificar um composto útil para tratar ou prevenir uma condição em um paciente
DK1784173T3 (da) Farmaceutisk sammensætning til forebyggelse og behandling af metaboliske knoglesygdomme indeholdende alpha-arylmethoxyacrylatderivater
PT1951692E (pt) Moduladores de ppar contendo oxazole e tiazole

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08J Incorrect entry in the gazette republished [chapter 8.10 patent gazette]

Free format text: REFERENTE A DESPACHO 8.6 NA RPI 2158 DE 15/05/2012. TEXTO CORRETO: 6A E 7A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2158 DE 15/05/2012 E DA REPUBLICACAO NA RPI 2162 DE 12/06/2012 E CONSIDERANDO A AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE.